Conference MDAngle: AANEM 2026 Myasthenia Gravis

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.The 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting will take place from September 29 to October 2 in Orlando, Florida, with myasthenia gravis (MG) featured prominently within the broader theme, “Beyond EMG: The Future of Neuromuscular Medicine.” The MGFA Scientific Session will include presentations spanning biomarkers and neuromuscular-junction pathology, respiratory monitoring, clinical trial outcome measures, and emerging treatment approaches. Scheduled presentations include efficacy and safety results from the phase 3 ADAPT SERON study of efgartigimod in acetylcholine receptor antibody (AChR)-negative generalized MG (gMG), data from the phase 3 NIMBLE trial comparing hospitalization rates with cemdisiran vs placebo, and phase 3 data from a 48-week study in China evaluating depth of response with the dual BAFF/APRIL inhibitor telitacicept in gMG. The program will also feature longer-term and re-treatment findings with autologous B cell-depleting monoclonal antibody (BCMA)-directed mRNA chimeric antigen receptor (CAR) T-cell therapy in the Descartes-08 trial as well as results from the phase 3 PREVAIL study of the investigational complement C5 inhibitor gefurulimab in patients with AChR antibody-positive gMG. Collectively, the 2026 session is expected to provide clinicians with updates on emerging therapeutic strategies and outcome measures in gMG. Amanda L. Hernandez, MD, PhDChief of Neuromuscular Medicine, Department of Neurology, University of Connecticut, Farmington, Connecticut“The [MG] landscape is only going to widen, and having an approach to how we navigate that with our patients is going to be incredibly crucial.”Preconference ConsiderationsAANEM 2026: Navigating an Expanding MG Treatment Landscape Dr Hernandez explains how the MG treatment landscape is expanding, with emphasis on matching therapy to serologic phenotype, clinical manifestations, and patient priorities. In the phase 3 ADAPT SERON trial, intravenous efgartigimod compared with placebo improved MG Activities of Daily Living outcomes in AChR antibody-seronegative gMG, including triple-seronegative disease, supporting FcRn inhibition as a promising strategy for this underserved population. Emerging BAFF/APRIL and CD19-directed CAR T-cell approaches may further broaden treatment options, in addition to inebilizumab, a CD19-directed BCMA. A priority is developing practical approaches to therapy selection, response assessment, and sequencing.Quick Clinical TakeawaysComing soon: Dr Hernandez highlights new data and progress regarding MG immediately following AANEM.How Will My Patients Benefit?Coming soon: Dr Hernandez reflects on how new data from AANEM will affect her patients with MG.ResourcesMDAngle Index